Pharma Mar S.A. — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

4 Recruiting

7 Completed trials

13 Countries active

10 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase I (Other)

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I/II: 3 Phase I (Other): 3 Phase I (FiH): 3

Oversight events:

2 serious breaches 1 temporary halt across 2 trials

View oversight register →

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Leiomyosarcoma metastatic 1 Small cell lung cancer 1

Top IMPs

LURBINECTEDIN 3 ECUBECTEDIN 1 PM54 1

All trials

12 total

A Basket Trial of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies Pending

2025-523774-16-00 Phase I/II 1 country PM54
Phase I Study of PM534 to Patients with Advanced Solid Tumors Recruiting

2024-519013-57-00 Phase I/II 1 country
Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors Recruiting

2024-517579-19-00 Phase I (Other) 1 country
Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients Recruiting

2023-508644-22-00 Phase I (FiH) 3 countries
Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors Recruiting

2024-513056-15-00 Phase I (FiH) 1 country
Phase I Study of Plitidepsin Administered Intravenously as a Single Dose in Healthy Volunteers Ended

2024-513664-25-00 Phase I (Other) 1 country
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Phase III 9 countries LURBINECTEDIN
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Phase III 11 countries LURBINECTEDIN
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected… Ended

2023-509688-25-00 Phase I (Other) 1 country
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with S… Ended

2024-514890-24-00 Phase II 1 country ECUBECTEDIN
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid … Ended

2024-511916-25-00 Phase I (FiH) 2 countries
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patien… Ended

2024-515394-10-00 Phase I/II 3 countries LURBINECTEDIN

Showing 1–12 of 12 trials

← All sponsors A–Z